By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Teznews24
  • जॉब-एजुकेशन
  • इकोनॉमी
  • टेक-ऑटो
  • मनोंरंजन
  • खेल जगत
  • ट्रेवल
  • स्वास्थ्य
Font ResizerAa
Teznews24Teznews24
Search
  • Quick Access
  • Categories
    • इकोनॉमी
    • मनोंरंजन
    • जॉब-एजुकेशन
    • टेक-ऑटो
    • खेल जगत

Top Stories

Explore the latest updated news!
ai powered diet plans needs a clinical reality check The Need for Clinical Accountability in AI-Powered Diet Plans, ETHealthworld

The Need for Clinical Accountability in AI-Powered Diet Plans, ETHealthworld

indias nutraceutical boom can regulation keep pace with growing consumer risks Can India's Nutraceutical Boom Survive Without Stricter Regulations?, ETHealthworld

Can India’s Nutraceutical Boom Survive Without Stricter Regulations?, ETHealthworld

maha fda warns of action on misleading claims with nutraceuticals mandates license Maharashtra FDA Cracks Down on Misleading Nutraceutical Claims: New Licensing Mandate, ETHealthworld

Maharashtra FDA Cracks Down on Misleading Nutraceutical Claims: New Licensing Mandate, ETHealthworld

Stay Connected

Find us on socials
248.1k Followers Like
61.1k Followers Follow
165k Subscribers Subscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Teznews24 > स्वास्थ्य > GLP-1 drugs tied to heart improvements in patients with obesity and heart failure, ETHealthworld
स्वास्थ्य

GLP-1 drugs tied to heart improvements in patients with obesity and heart failure, ETHealthworld

admin
Last updated: 2026/11/21 at 4:18 AM
By admin Add a Comment
Share
SHARE

Contents
Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox.All about ETHealthworld industry right on your smartphone!

136042852 GLP-1 drugs tied to heart improvements in patients with obesity and heart failure, ETHealthworld

GLP-1 DRUGS MAY STRENGTHEN FAILING HEARTS

Use of GLP-1 drugs by patients with obesity and heart failure was associated with significant heart muscle improvements, according to a study by Mayo Clinic researchers presented at the obesity meeting.

Everyone in the study had heart failure with reduced ejection fraction, meaning the heart’s left ventricle was only weakly pushing blood out toward the body.

After one year, those taking GLP-1 medications showed significantly greater improvements in left ventricular size, shape, structure, and function than a closely matched control group of patients with obesity, researchers reported.

Those on GLP-1 therapy were taking either semaglutide, sold by Novo Nordisk as Wegovy and Ozempic, or tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro.

Not surprisingly, the 146 patients in the GLP-1 group had significantly greater total body-weight loss than the 237 who were not taking the medicines.

The study was only designed to analyze changes at one year, but so-called “exploratory two-year analyses” – intended to generate new hypotheses for future studies – showed continued improvements in left ventricular ejection fraction and heart size, the researchers said.

Most of the improvements remained significant even after accounting for weight changes, suggesting that some of the positive effects were due to the drugs themselves rather than weight reduction, the researchers also reported.

A week earlier at the American Heart Association’s Scientific Sessions in Chicago, a separate team of Mayo Clinic researchers reported on 81 adults with obesity and heart failure with preserved ejection fraction – that is, the left ventricle wasn’t particularly weak – who received semaglutide or a placebo for 52 weeks.

Treatment with semaglutide improved pressures inside the heart during exercise and at rest and was associated with remission of heart failure in more than half of treated patients, the researchers reported in Nature Medicine.

ZEPBOUND CAN BE COST-SAVING, ELI LILLY SAYS

Eli Lilly’s expensive obesity drug Zepbound is ultimately cost-saving over time, according to data presented by the Indianapolis-based drugmaker.

Researchers compared trends in healthcare costs and utilization among more than 171,000 adults treated for at least a year with Zepbound for weight management, and the same number of similar but untreated individuals. No one in the study had diabetes.

During follow-up, healthcare costs remained stable in the Zepbound group but rose steadily in the control group. In one analysis, healthcare costs per month in patients not receiving Zepbound grew by an estimated $29 at 3-6 months, $82 at 6-12 months, and $120 at 12-18 months.

Zepbound-treated patients had 7% fewer hospitalizations and emergency department visits at 3-6 months. That climbed to 18% fewer for up to 12 months and a 34% reduction at 12-18 months.

“These findings suggest that beyond its clinical benefits, tirzepatide may deliver growing economic value over time,” Lilly’s researchers concluded in a brief summary of their presentation known as an abstract.

They did not report on what patients had paid for the medication or whether the savings completely offset the costs.

Zepbound can cost more than $1,000 per month without insurance. A recent study by CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month, as reduced use of medical services lowers spending enough to offset drug costs.

A separate study presented at the obesity meeting suggests GLP-1 use is associated with improved labor market outcomes.

Using data from a nationally representative internet panel of approximately 15,000 US adults, researchers found improvements in labor-force participation and ongoing improvements in productivity, following initiation of the drugs.

The results are relevant for employers considering coverage decisions, the researchers said, as many companies have dropped coverage of the medications due to overall costs.

“If GLP-1s improve worker productivity and participation, expanded access may yield returns in the form of higher output and reduced absenteeism,” they said.

GLP-1 USE BY SENIORS LINKED WITH FEWER FALLS

Among older adults with obesity, GLP-1 use was associated with lower risks of falls and wheelchair dependence, according to a two-year study that tracked more than 122,000 patients age 65 and older without impaired mobility.

In these patients who were taking GLP-1 drugs or the common diabetes medication metformin, GLP-1 use was associated with a 13% lower risk of falls and a 37% lower risk of new-onset wheelchair dependence, the researchers reported.

The study did not compare patterns of weight loss, and it cannot prove the GLP-1 drugs prevented falls and wheelchair dependence.

Still, the researchers say, the findings suggest a potential role for the drugs in preserving independence among older adults with obesity, with implications for quality of life and healthcare utilization.

  • Published On Nov 21, 2026 at 07:30 AM IST

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!


health barcode GLP-1 drugs tied to heart improvements in patients with obesity and heart failure, ETHealthworld

Source link

TAGGED: GLP-1 drugs, healthcare costs, heart failure, heart improvements, obesity therapy
Share This Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related Stories

Uncover the stories that related to the post!
ai powered diet plans needs a clinical reality check The Need for Clinical Accountability in AI-Powered Diet Plans, ETHealthworld
स्वास्थ्य

The Need for Clinical Accountability in AI-Powered Diet Plans, ETHealthworld

indias nutraceutical boom can regulation keep pace with growing consumer risks Can India's Nutraceutical Boom Survive Without Stricter Regulations?, ETHealthworld
स्वास्थ्य

Can India’s Nutraceutical Boom Survive Without Stricter Regulations?, ETHealthworld

maha fda warns of action on misleading claims with nutraceuticals mandates license Maharashtra FDA Cracks Down on Misleading Nutraceutical Claims: New Licensing Mandate, ETHealthworld
स्वास्थ्य

Maharashtra FDA Cracks Down on Misleading Nutraceutical Claims: New Licensing Mandate, ETHealthworld

bajaj to expand into healthcare with 2500 cr initial investment in pune Bajaj Group Invests ₹2500 Crore to Transform Healthcare in Pune, ETHealthworld
स्वास्थ्य

Bajaj Group Invests ₹2500 Crore to Transform Healthcare in Pune, ETHealthworld

blackstone backed aster dm in talks to acquire rival hospitals in deeper india push Aster DM in $150 Million Talks to Acquire Hospitals from Narayana Hrudayalaya in India, ETHealthworld
स्वास्थ्य

Aster DM in $150 Million Talks to Acquire Hospitals from Narayana Hrudayalaya in India, ETHealthworld

health of states bihar per capita spend lowest sikkims highest Bihar per capita spend lowest, Sikkim's highest, ETHealthworld
स्वास्थ्य

Bihar per capita spend lowest, Sikkim’s highest, ETHealthworld

delhi ncr leads india in robotic cardiac surgery experts see india overtaking us by 2031 India's Leading Hub for Robotic Cardiac Surgery, Poised to Overtake the US by 2031, ETHealthworld
स्वास्थ्य

India’s Leading Hub for Robotic Cardiac Surgery, Poised to Overtake the US by 2031, ETHealthworld

white blood cell dna may strengthen not dilute cancer signals in blood tests indian study White Blood Cell DNA Enhances Cancer Detection Accuracy in Blood Tests, ETHealthworld
स्वास्थ्य

White Blood Cell DNA Enhances Cancer Detection Accuracy in Blood Tests, ETHealthworld

Show More
teznews24 teznews24
  • Categories:
  • Fashion
  • Travel
  • Sport
  • Adverts

Quick Links

About US

  • Adverts
  • Our Jobs
  • Term of Use
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Welcome Back!

Sign in to your account

Lost your password?